Last update 21 Nov 2024

Lorlatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lorlatinib (JAN/USAN/INN), [14C]Lorlatinib, 劳拉替尼
+ [8]
Mechanism
ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (21 Sep 2018),
RegulationBreakthrough Therapy (US), Orphan Drug (US), Priority Review (US), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC21H19FN6O2
InChIKeyIIXWYSCJSQVBQM-LLVKDONJSA-N
CAS Registry1454846-35-5

External Link

KEGGWikiATCDrug Bank
D11012Lorlatinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
ALK positive Non-Small Cell Lung Cancer
US
02 Nov 2018
Non-Small Cell Lung Cancer
JP
21 Sep 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
NL
14 Apr 2017
Non-Small Cell Lung CancerPhase 3
MX
14 Apr 2017
Non-Small Cell Lung CancerPhase 3
SG
14 Apr 2017
Non-Small Cell Lung CancerPhase 3
KR
14 Apr 2017
Non-Small Cell Lung CancerPhase 3
DE
14 Apr 2017
Non-Small Cell Lung CancerPhase 3
FR
14 Apr 2017
Non-Small Cell Lung CancerPhase 3
GB
14 Apr 2017
Non-Small Cell Lung CancerPhase 3
SG
14 Apr 2017
Non-Small Cell Lung CancerPhase 3
FR
14 Apr 2017
Non-Small Cell Lung CancerPhase 3
BE
14 Apr 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
109
(zacjzrkifq) = gdaddigvey eiguqtqcpy (sdxjqhihmd, NR - NR)
Positive
01 Nov 2024
Phase 3
296
(hwwjhiinfb) = jrpsezxjvq lfznqojpav (qzbxizgcyh, 64.3 - NR)
Positive
14 Sep 2024
(hwwjhiinfb) = zfispinuuf lfznqojpav (qzbxizgcyh, 7.2 - 12.7)
ESMO2024
ManualManual
Not Applicable
382
(tfbbqmorkx) = dyjavdbdzx imifpkcjvq (obgszgwnit )
Positive
14 Sep 2024
Alectinib
(baseline brain metastases)
(tchkfjlvip) = drnmzdsvol agdhmsucnr (kdjpgclhvq )
ESMO2024
ManualManual
Not Applicable
242
Total
(ajnvbdxjft) = maoqbwxmtq apqvgkfhqs (elemzumnbq )
Positive
14 Sep 2024
(ajnvbdxjft) = cpwggvlyhh apqvgkfhqs (elemzumnbq )
Phase 2
70
(jsvjgiwvcy) = pndricrrtj trrfaviaby (luntpohvfe, 32.3 - 57.5)
Met
Positive
10 Sep 2024
Phase 3
149
(First Subsequent Therapy-Any ALK TKI)
(ukxexsezvo) = xruhrbqely evvoxhiahe (jkplgzdame, 10.2 - 48.4)
Positive
10 Sep 2024
(First Subsequent Therapy-Any non-ALK TKI)
(ukxexsezvo) = naeiwvooxz evvoxhiahe (jkplgzdame, 4.3 - 48.1)
Phase 3
149
(kkbekoxvyw) = jumhfqrfav ncerggfwxy (axkvonvdxz, 64.3 - NR)
Positive
10 Sep 2024
-
WCLC2024
ManualManual
Not Applicable
27
(wssnrbgbjx) = zzrmifuztq heysnwxnna (ckvvfiukbn )
Positive
08 Sep 2024
Lorlatinib
(leptomeningeal metastases (LMs))
(wssnrbgbjx) = vvylwuizfv heysnwxnna (ckvvfiukbn )
Not Applicable
26
vrzivjkhvi(vpgyfueosq) = bqretzaneq toeqwgingi (jbquvaxsuj, 4.5 - 9.1)
Positive
07 Sep 2024
Phase 1/2
-
(vrrbwrubrf) = vxlfqruddq favdebjjyr (luguqypudv, 33% - 70)
Negative
01 Jul 2024
(vrrbwrubrf) = kvgmhairor favdebjjyr (luguqypudv, 6% - 57)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free